Classification of non-small cell lung cancer based on copy number alterations

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  Li, Bi Qing ^b   You, Jin ^b   Huang, Tao ^c   Cai, Yu Dong ^a  

^a SHANGHAI UNIVERSITY   (China)

^b Chinese Academy of Sciences   (China)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; ARTICLE; CANCER CLASSIFICATION; CANCER STAGING; CHROMOSOME STRUCTURE; CLASSIFIER; COPY NUMBER VARIATION; EARLY CANCER; EPIGENETICS; FOCAL ADHESION; GENE PROBE; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; NUCLEOTIDE SEQUENCE; SIGNAL TRANSDUCTION; WNT SIGNALING PATHWAY;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; DNA COPY NUMBER VARIATIONS; GENE DOSAGE; HUMANS; LUNG; LUNG NEOPLASMS;

EID: 84895508672     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088300     Document Type: Article

References (70)

1. Siegel R, Naishadham D, Jemal A Cancer statistics, 2012. CA: A Cancer Journal for Clinicians 62: 10-29.
2. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, et al. (2011) International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 6: 244-285.
3. Perez-Moreno P, Brambilla E, Thomas R, Soria J-C Squamous Cell Carcinoma of the Lung: Molecular Subtypes and Therapeutic Opportunities. Clinical Cancer Research 18: 2443-2451.
4. Subramanian J, Govindan R (2007) Lung Cancer in Never Smokers: A Review. Journal of Clinical Oncology 25: 561-570. (Pubitemid 350002964)
5. Travis WD (2011) Pathology of Lung Cancer. Clinics in chest medicine 32: 669-692.
6. Kenfield SA, Wei EK, Stampfer MJ, Rosner BA, Colditz GA (2008) Comparison of aspects of smoking among the four histological types of lung cancer. Tobacco Control 17: 198-204.
7. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, et al. (2009) The Differential Efficacy of Pemetrexed According to NSCLC Histology: A Review of Two Phase III Studies. The Oncologist 14: 253-263.
8. Cohen MH, Gootenberg J, Keegan P, Pazdur R (2007) FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer. Oncologist 12: 713-718. (Pubitemid 47036205)
9. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, et al. (2006) Paclitaxel-Carboplatin Alone or with Bevacizumab for Non-Small-Cell Lung Cancer. New England Journal of Medicine 355: 2542-2550. (Pubitemid 44917502)
10. Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, et al. (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 22: 2184-2191. (Pubitemid 41095154)
11. Travis WD, Rekhtman N, Riley GJ, Geisinger KR, Asamura H, et al. (2010) Pathologic Diagnosis of Advanced Lung Cancer Based on Small Biopsies and Cytology: A Paradigm Shift. Journal of Thoracic Oncology 5: 411-414 410.1097/JTO.1090b1013e3181d1057f1096e.
12. Kargi A, Gurel D, Tuna B (2007) The Diagnostic Value of TTF-1, CK 5/6, and p63 Immunostaining in Classification of Lung Carcinomas. Applied Immunohistochemistry & Molecular Morphology 15: 415-420 410.1097/PAI.1090- b1013e31802fab31875.
13. Pao W, Chmielecki J (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer 10: 760-774.
14. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-1703.
15. Baudis M (2007) Genomic imbalances in 5918 malignant epithelial tumors: an explorative meta-analysis of chromosomal CGH data. BMC Cancer 7: 226.
16. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
17. Huang Y-T, Lin X, Chirieac LR, McGovern R, Wain JC, et al. (2011) Impact on Disease Development, Genomic Location and Biological Function of Copy Number Alterations in Non-Small Cell Lung Cancer. PLoS ONE 6: e22961.
18. Tonon G, Wong K-K, Maulik G, Brennan C, Feng B, et al. (2005) High-resolution genomic profiles of human lung cancer. Proceedings of the National Academy of Sciences of the United States of America 102: 9625-9630. (Pubitemid 40981731)
19. Huang YT, Lin X, Chirieac LR, McGovern R, Wain JC, et al. (2011) Impact on disease development, genomic location and biological function of copy number alterations in non-small cell lung cancer. Plos One 6: e22961.
20. Peng H, Long F, Ding C (2005) Feature selection based on mutual information: criteria of max-dependency, max-relevance, and min-redundancy. IEEE Trans Pattern Anal Mach Intell 27: 1226-1238. (Pubitemid 41245053)
21. Friedman JH, Baskett F, Shustek LJ (1975) An algorithm for finding nearest neighbors. IEEE Transaction on Information Theory C-24: 1000-1006.
22. Denoeux T (1995) A k-nearest neighbor classification rule based on Dempster-Shafer theory. IEEE Transactions on Systems, Man and Cybernetics 25.: 804-813.
23. Li BQ, Huang T, Liu L, Cai YD, Chou KC (2012) Identification of colorectal cancer related genes with mRMR and shortest path in protein-protein interaction network. PLoS ONE 7: e33393.
24. Li B-Q, Hu L-L, Niu S, Cai Y-D, Chou K-C (2012) Predict and analyze S-nitrosylation modification sites with the mRMR and IFS approaches. Journal of Proteomics 75: 1654-1665.
25. Huang T, Chen L, Cai Y-D, Chou K-C (2011) Classification and analysis of regulatory pathways using graph property, biochemical and physicochemical property, and functional property. PLoS ONE 6: e25297.
26. Huang T, Cui W, Hu L, Feng K, Li YX, et al. (2009) Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles. PLoS ONE 4: e8126.
27. Gao Y-F, Li B-Q, Cai Y-D, Feng K-Y, Li Z-D, et al. (2013) Prediction of active sites of enzymes by maximum relevance minimum redundancy (mRMR) feature selection. Molecular BioSystems.
28. Chou KC (2011) Some remarks on protein attribute prediction and pseudo amino acid composition (50th Anniversary Year Review). Journal of Theoretical Biology 273: 236-247
29. Zhang N, Li B-Q, Gao S, Ruan J-S, Cai Y-D (2012) Computational prediction and analysis of protein [gamma]-carboxylation sites based on a random forest method. Molecular BioSystems 8: 2946-2955.
30. Huang T, Xu Z, Chen L, Cai YD, Kong X (2011) Computational analysis of HIV-1 resistance based on gene expression profiles and the virus-host interaction network. Plos One 6: e17291.
31. Li B-Q, Feng K-Y, Chen L, Huang T, Cai Y-D (2012) Prediction of Protein-Protein Interaction Sites by Random Forest Algorithm with mRMR and IFS. PLoS ONE 7: e43927.
32. Li B-Q, Hu L-L, Chen L, Feng K-Y, Cai Y-D, et al. (2012) Prediction of Protein Domain with mRMR Feature Selection and Analysis. PLoS One 7: e39308.
33. Li B-Q, Cai Y-D, Feng K-Y, Zhao G-J (2012) Prediction of Protein Cleavage Site with Feature Selection by Random Forest. PLoS One 7: e45854.
34. Chang JT, Nevins JR (2006) GATHER: a systems approach to interpreting genomic signatures. Bioinformatics 22: 2926-2933. (Pubitemid 44811565)
35. Uematsu K, He B, You L, Xu Z, McCormick F, et al. (0000) Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene 22: 7218-7221.
36. You L, He B, Xu Z, Uematsu K, Mazieres J, et al. (2004) Inhibition of Wnt-2-mediated signaling induces programmed cell death in non-small-cell lung cancer cells. Oncogene 23: 6170-6174. (Pubitemid 39178870)
37. Berrier AL, Yamada KM (2007) Cell-matrix adhesion. Journal of Cellular Physiology 213: 565-573. (Pubitemid 350058247)
38. Frisch SM, Vuori K, Ruoslahti E, Chan-Hui PY (1996) Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 134: 793-799. (Pubitemid 26269148)
39. Carelli S, Zadra G, Vaira V, Falleni M, Bottiglieri L, et al. (2006) Up-regulation of focal adhesion kinase in non-small cell lung cancer. Lung Cancer 53: 263-271. (Pubitemid 44209282)
40. Hanahan D, Weinberg Robert A (2011) Hallmarks of Cancer: The Next Generation. Cell 144: 646-674.
41. Pei J, Balsara BR, Li W, Litwin S, Gabrielson E, et al. (2001) Genomic imbalances in human lung adenocarcinomas and squamous cell carcinomas. Genes, Chromosomes and Cancer 31: 282-287. (Pubitemid 32521759)
42. Lockwood WW, Chari R, Coe BP, Thu KL, Garnis C, et al. Integrative genomic analyses identify BRF2 as a novel lineage-specific oncogene in lung squamous cell carcinoma. PLoS medicine 7: e1000315.
43. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, et al. (2002) p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 416: 560-564. (Pubitemid 34288861)
44. Kim MJ, Shin HC, Shin KC, Ro JY Best immunohistochemical panel in distinguishing adenocarcinoma from squamous cell carcinoma of lung: tissue microarray assay in resected lung cancer specimens. Annals of Diagnostic Pathology.
45. Pasquale EB Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer 10: 165-180.
46. Fukai J, Yokote H, Yamanaka R, Arao T, Nishio K, et al. (2008) EphA4 promotes cell proliferation and migration through a novel EphA4-FGFR1 signaling pathway in the human glioma U251 cell line. Molecular Cancer Therapeutics 7: 2768-2778.
47. Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, et al. (2009) Expression of the Receptor Tyrosine Kinase EphA2 Is Increased in Smokers and Predicts Poor Survival in Non-small Cell Lung Cancer. Clinical Cancer Research 15: 4423-4430.
48. Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, et al. EphA2 Mutation in Lung Squamous Cell Carcinoma Promotes Increased Cell Survival, Cell Invasion, Focal Adhesions, and Mammalian Target of Rapamycin Activation. Journal of Biological Chemistry 285: 18575-18585.
49. Bennin DA, Don ASA, Brake T, McKenzie JL, Rosenbaum H, et al. (2002) Cyclin G2 Associates with Protein Phosphatase 2A Catalytic and Regulatory B9Subunits in Active Complexes and Induces Nuclear Aberrations and a G1/S Phase Cell Cycle Arrest. Journal of Biological Chemistry 277: 27449-27467. (Pubitemid 34951766)
50. Dong J, Hu Z, Wu C, Guo H, Zhou B, et al. Association analyses identify multiple new lung cancer susceptibility loci and their interactions with smoking in the Chinese population. Nat Genet 44: 895-899.
51. Høye AM, Couchman JR, Wewer UM, Fukami K, Yoneda A The newcomer in the integrin family: Integrin a9 in biology and cancer. Advances in Biological Regulation 52: 326-339.
52. Anedchenko EA, Dmitriev AA, Krasnov GS, Kondrat'eva TT, Kopantsev EP, et al. (2008) Down-regulation of RBSP3/CTDSPL, NPRL2/G21, RASSF1A, ITGA9, HYAL1 and HYAL2 genes in non-small cell lung cancer. Mol Biol (Mosk) 42: 965-976.
53. Dmitriev AA, Kashuba VI, Haraldson K, Senchenko VN, Pavlova TV, et al. Genetic and epigenetic analysis of non-small cell lung cancer with NotI-microarrays. Epigenetics 7: 502-513.
54. Hussenet T, Dali S, Exinger J, Monga B, Jost B, et al. SOX2 Is an Oncogene Activated by Recurrent 3q26.3 Amplifications in Human Lung Squamous Cell Carcinomas. Plos One 5: e8960.
55. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, et al. (2009) SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 41: 1238-1242.
56. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, et al. (2007) Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors. Cell 131: 861-872. (Pubitemid 350138099)
57. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, et al. (1996) Fhit, a Putative Tumor Suppressor in Humans, Is a dinucleoside 5′,5‴-P1,P3-triphosphate Hydrolase. Biochemistry 35: 11529-11535. (Pubitemid 26303669)
58. Roz L, Andriani F, Ferreira CG, Giaccone G, Sozzi G (2004) The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression. Oncogene 23: 9102-9110. (Pubitemid 40013077)
59. Tseng JE, Kemp BL, Khuri FR, Kurie JM, Lee JS, et al. (1999) Loss of Fhit Is Frequent in Stage I Non-Small Cell Lung Cancer and in the Lungs of Chronic Smokers. Cancer Research 59: 4798-4803. (Pubitemid 29472879)
60. Toledo G, Sola JJ, Lozano MD, Soria E, Pardo J (2004) Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer. Mod Pathol 17: 440-448. (Pubitemid 41646599)
61. Fusco C, Reymond A, Zervos AS (1998) Molecular cloning and characterization of a novel retinoblastoma-binding protein. Genomics 51: 351-358. (Pubitemid 28413201)
62. Schaeper U, Subramanian T, Lim L, Boyd JM, Chinnadurai G (1998) Interaction between a cellular protein that binds to the C-terminal region of adenovirus E1A (CtBP) and a novel cellular protein is disrupted by E1A through a conserved PLDLS motif. J Biol Chem 273: 8549-8552. (Pubitemid 28176126)
63. Yu X, Chen J (2004) DNA damage-induced cell cycle checkpoint control requires CtIP, a phosphorylation-dependent binding partner of BRCA1 C-terminal domains. Mol Cell Biol 24: 9478-9486. (Pubitemid 39391684)
64. Yu X, Fu S, Lai M, Baer R, Chen J (2006) BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. Genes Dev 20: 1721-1726. (Pubitemid 43992880)
65. Greenberg RA, Sobhian B, Pathania S, Cantor SB, Nakatani Y, et al. (2006) Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. Genes Dev 20: 34-46. (Pubitemid 43042666)
66. Sartori AA, Lukas C, Coates J, Mistrik M, Fu S, et al. (2007) Human CtIP promotes DNA end resection. Nature 450: 509-514. (Pubitemid 350190253)
67. Daraselia N, Wang Y, Budoff A, Lituev A, Potapova O, et al. (2012) Molecular signature and pathway analysis of human primary squamous and adenocarcinoma lung cancers. Am J Cancer Res 2: 93-103.
68. Veugelers M, Vermeesch J, Reekmans G, Steinfeld R, Marynen P, et al. (1997) Characterization of glypican-5 and chromosomal localization of human GPC5, a new member of the glypican gene family. Genomics 40: 24-30. (Pubitemid 27108243)
69. Li Y, Sheu CC, Ye Y, de Andrade M, Wang L, et al. (2010) Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol 11: 321-330.
70. Yang X, Zhang Z, Qiu M, Hu J, Fan X, et al. Glypican-5 is a novel metastasis suppressor gene in non-small cell lung cancer. Cancer Letters.